U.S. CDC Advisory Committee Unanimously Recommends Routine Use Of Beyfortus To Protect Infants Against RSV Disease
Portfolio Pulse from Benzinga Newsdesk
The U.S. CDC Advisory Committee has unanimously recommended the routine use of Beyfortus, a drug developed by Sanofi and AstraZeneca, to protect infants against RSV disease. The recommendation applies to all infants below 8 months of age and children aged 8 to 19 months at increased risk of severe RSV disease. The Committee also voted to include Beyfortus in the Vaccines for Children program. Beyfortus is the first RSV prevention approved to protect all infants in the U.S. and will be available ahead of the 2023-2024 RSV season.
August 04, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Beyfortus, developed in partnership with Sanofi, has been recommended for routine use by the U.S. CDC Advisory Committee. This could potentially boost AstraZeneca's revenues as the drug will be available ahead of the 2023-2024 RSV season.
The unanimous recommendation by the CDC Advisory Committee for the routine use of Beyfortus could lead to increased sales and revenues for AstraZeneca. The inclusion of the drug in the Vaccines for Children program also expands its potential market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi's Beyfortus, developed in partnership with AstraZeneca, has been recommended for routine use by the U.S. CDC Advisory Committee. This could potentially boost Sanofi's revenues as the drug will be available ahead of the 2023-2024 RSV season.
The unanimous recommendation by the CDC Advisory Committee for the routine use of Beyfortus could lead to increased sales and revenues for Sanofi. The inclusion of the drug in the Vaccines for Children program also expands its potential market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100